News

Pulmatrix has licensed PUR0200, its investigative inhaled treatment for people with chronic obstructive pulmonary disease (COPD), to the Vectura Group to speed its entry into the U.S. market. Vectura, a company specialized in inhaled airway products, will now be responsible for all future development costs to advance the product in the…

An allergic sensitization to the Aspergillus fumigatus fungus may lead to bronchiectasis in patients with chronic obstructive pulmonary disease (COPD), Belgian researchers suggest. The study, “Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD,” was published in the International Journal of Chronic Obstructive Pulmonary…

A new computer model based on anatomical and experimental information can predict changes in lung function caused by chronic inflammation. Developed by researchers at Rutgers University in New Jersey, this virtual system can help identify the different damaging and remodeling factors that contribute to lung function changes in several respiratory…

Propeller Health and GlaxoSmithKline (GSK) will extend their collaboration in which patients with chronic obstructive pulmonary disease (COPD) and asthma use Propeller’s clip-on sensor and software platform with GSK’s Ellipta Inhaler to help them manage their illnesses. The new extended partnership, first announced in 2015, will allow Propeller and GSK to…

The risk of visits to the emergency room or hospitalization for acute exacerbations due to chronic obstructive pulmonary disease (COPD) significantly decreases in obese patients after they undergo bariatric surgery, researchers found. The study, “Reduced Risk of Acute Exacerbation of COPD After Bariatric Surgery: A Self-Controlled…

LAMA (long-acting muscarinic antagonist) treatments may be more beneficial to people with stable chronic obstructive pulmonary disease (COPD) than those with LABA (long-acting beta2-agonist), especially in patients at risk of frequent exacerbations, according to results of a recent review study. Both LAMA and LABA are long-lasting bronchodilators, widely used as first-line treatments…

Apria Healthcare has started a program to help COPD patients get the most out of mechanical ventilation by not only having respiratory therapists train them but also visit their homes to make sure they’re using it correctly. The Apria Clinical Evidence, or ACE, program is aimed at improving the healthcare outcomes…

Verona Pharma recently announced clinical development updates and interim results for the first half of 2017 for RPL554 as a treatment for chronic obstructive pulmonary disease (COPD) with the start of four new clinical trials. Verona developed RPL554 as a nebulized dual-inhibitor of the enzymes phosphodiesterase 3 and 4…

The European Union has approved Trimbow as a maintenance treatment for adults with moderate to severe chronic obstructive pulmonary disease. Trimbow, developed by Italy’s Chiesi Group, is the first triple-combination inhaler for COPD. It contains the inhaled corticosteroid beclometasone dipropionate, the β2 agonist formoterol fumarate, and the muscarinic antagonist glycopyrronium.

Verona Pharma recently dosed the first patients in its Phase 2b clinical trial evaluating RPL554 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). RPL554 is a first-in-class dual inhibitor of the enzymes phosphodiesterase 3 and 4. The drug has anti-inflammatory and bronchodilator properties. An inhaled formulation of…